HIGHLIGHTS
- who: Pr and colleagues from the Samara State Medical University, Samara, Russia have published the Article: u041fu041eu041cu041eu0429u042c u041fu0420u0410u041au0422u0418u0427u0415u0421u041au041eu041cu0423 u0412u0420u0410u0427u0423 / GUIDELINES FOR PRACTITIONERS u042d in t ea, in the Journal: (JOURNAL)
- what: The Article describes the efficacy and safety of dupilumab in the treatment of severe continuously relapsing atopic dermatitis.
SUMMARY
Ah dupilumab Source of funding: the work was done and published through financing at the place of work of the authors. Efficacy and safety of the first targeted biological drug dupilumab in the treatment of severe continuously relapsing atopic dermatitis. B . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.